Jiangxi Fushine Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the comprehensive research, development, manufacturing, and global distribution of active pharmaceutical ingredients and key pharmaceutical intermediates. The company is a prominent force in the production of anti-infective drug raw materials, notably offering a broad portfolio of β-lactamase inhibitors and carbapenem series antibiotics, with an established integrated value chain from initial components to finished APIs. Beyond its core pharmaceutical offerings, which also include antiviral drug intermediates and select finished formulations like argatroban injection and doxycycline hydrochloride dispersible tablets, Jiangxi Fushine has strategically diversified into advanced materials. This includes being a significant supplier of lithium-ion battery electrolyte additives such as vinylene carbonate (VC), and exploring the synthetic biology sector with microbial protein and other bio-fermentation products. Established in 2002 and headquartered in Jingdezhen, China, the company actively serves both domestic and international markets, exporting its diverse range of products to over twenty countries. Jiangxi Fushine Pharmaceutical was formerly known as Jingdezhen Fuxiang Pharmaceutical Co., Ltd. until its name change in August 2012. The company maintains a strong commitment to innovation, quality management, and has successfully passed multiple international inspections, including recent US FDA on-site audits.